IgE
Alexa Fluor 350
Common Laser: | 355 |
---|---|
Common Filter: | 450/50 |
Excitation Peak: | 346 |
Emission Peak: | 442 |
Alexa Fluor™ 350 (AF350, Alexa 350) has an excitation peak at 346 nm and an emission peak at 442 nm, and is spectrally similar in size, brightness and application to AMCA, DyLight™ 350 and CF®350. Alexa 350 is most commonly used in flow cytometery and fluorescence microscopy applications.
Popular IgE Alexa Fluor 350 Antibodies
Company / SKU |
Applications | Marker / Reactivity |
Host / Isotype / Clone |
Size / Price |
Details | |
---|---|---|---|---|---|---|
Novus Biologicals, a Bio-Techne brand NBP3-28478AF350 |
FC,ELISA,Functional | IgE Human |
Human IgG1 omalizumab |
100 μl $379 |
Details | |
Novus Biologicals, a Bio-Techne brand NB110-8339AF350 |
WB,ELISA | IgE Human |
Mouse IgG1 XTE4 |
200 μl $479 |
Details | |
Novus Biologicals, a Bio-Techne brand NB500-471AF350 |
ELISA | IgE Human |
Mouse IgG 4G7 |
0.1 ml $409 |
Details | |
Novus Biologicals, a Bio-Techne brand NBP3-28559AF350 |
FC,ELISA,Functional | IgE Human |
Human IgG1 talizumab |
100 μl $379 |
Details | |
Novus Biologicals, a Bio-Techne brand NB110-8338AF350 |
ELISA | IgE Human |
Mouse IgG1 E411cc |
200 μl $479 |
Details | |
Novus Biologicals, a Bio-Techne brand NB500-470AF350 |
FC,ELISA | IgE Human |
Mouse IgG1 BE5 |
0.1 ml $409 |
Details | |
Novus Biologicals, a Bio-Techne brand NBP3-28368AF350 |
FC,ELISA,Functional | IgE Human |
Human IgG1 quilizumab |
100 μl $379 |
Details | |
Novus Biologicals, a Bio-Techne brand NBP3-28557AF350 |
FC,ELISA,Functional | IgE Human |
Human IgG1 ligelizumab |
100 μl $379 |
Details | |
Novus Biologicals, a Bio-Techne brand NB500-472AF350 |
FC,ELISA | IgE Human |
Mouse IgG1 4H10 |
0.1 ml $409 |
Details | |
Novus Biologicals, a Bio-Techne brand NBP1-42334AF350 |
ELISA,IHC,IHC-Fr | IgE Mouse |
Rat IgG1 κ LO-ME-3 |
200 μl $489 |
Details | |
Novus Biologicals, a Bio-Techne brand NB110-8331AF350 |
ELISA | IgE Human |
Mouse IgG2a 5D4cc |
200 μl $479 |
Details | |
Browse IgE / Alexa Fluor 350 antibodies. |